In vivo imaging of alpha-synuclein with antibody-based PET
Open Access
- 8 February 2022
- journal article
- research article
- Published by Elsevier in Neuropharmacology
- Vol. 208, 108985
Abstract
No abstract availableKeywords
This publication has 58 references indexed in Scilit:
- Large α-synuclein oligomers inhibit neuronal SNARE-mediated vesicle dockingProceedings of the National Academy of Sciences, 2013
- A Progressive Mouse Model of Parkinson's Disease: The Thy1-aSyn (“Line 61”) MiceNeurotherapeutics, 2012
- In vivo demonstration that α-synuclein oligomers are toxicProceedings of the National Academy of Sciences, 2011
- The lipid peroxidation products 4-oxo-2-nonenal and 4-hydroxy-2-nonenal promote the formation of α-synuclein oligomers with distinct biochemical, morphological, and functional propertiesFree Radical Biology and Medicine, 2011
- Synergistic Interactions between Aβ, Tau, and α-Synuclein: Acceleration of Neuropathology and Cognitive DeclineThe Journal of Neuroscience, 2010
- Engineering and expression of a chimeric transferrin receptor monoclonal antibody for blood–brain barrier delivery in the mouseBiotechnology and Bioengineering, 2008
- In vitro high affinity α‐synuclein binding sites for the amyloid imaging agent PIB are not matched by binding to Lewy bodies in postmortem human brain1Journal of Neurochemistry, 2008
- In VitroCharacterization of Pittsburgh Compound-B Binding to Lewy BodiesJournal of Neuroscience, 2007
- Motor subtype and cognitive decline in Parkinson's disease, Parkinson's disease with dementia, and dementia with Lewy bodiesJournal of Neurology, Neurosurgery & Psychiatry, 2006
- Imaging brain amyloid in Alzheimer's disease with Pittsburgh Compound‐BAnnals of Neurology, 2004